| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/11/2010 | WO2010028173A2 Method of treating atrial fibrillation |
| 03/11/2010 | WO2010028067A1 Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| 03/11/2010 | WO2010027762A1 Indolizine inhibitors of leukotriene production |
| 03/11/2010 | WO2010027572A2 Reducing cholesterol levels with combined use of querceting and statin |
| 03/11/2010 | WO2010027500A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 03/11/2010 | WO2010027005A1 Substituted amine derivative and medicinal composition comprising same as the active ingredient |
| 03/11/2010 | WO2010027002A1 Ring-fused morpholine derivative having pi3k-inhibiting activity |
| 03/11/2010 | WO2010026764A1 Electron irradiated physiologically isotonic solution, electron irradiation device for electron irradiated physiologically isotonic solution, and organ storage container |
| 03/11/2010 | WO2010026255A1 Process for preparing olmesartan medoxomil intermediate |
| 03/11/2010 | WO2010025856A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| 03/11/2010 | WO2010011821A3 Dual-acting antihypertensive agents |
| 03/11/2010 | WO2009156099A8 6-substituted isoquinolines and isoquinolinones |
| 03/11/2010 | WO2009152415A3 Reducing myocardial reperfusion injury by the combination therapy of protein kinase a activation and b1-adrenergic receptor blockade |
| 03/11/2010 | WO2009150214A3 Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
| 03/11/2010 | WO2009109654A3 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxcr1 and p40 |
| 03/11/2010 | WO2009080818A3 Guanidine based compounds |
| 03/11/2010 | WO2008094909A3 Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions |
| 03/11/2010 | US20100063159 Use of dapsone as a neuroprotector in cerebral infarction |
| 03/11/2010 | US20100063144 Compounds and uses thereof |
| 03/11/2010 | US20100063100 Modulators of aldehyde dehydrogenase activity and methods of use thereof |
| 03/11/2010 | US20100063095 Hemiasterlin derivatives and uses thereof in the treatment of cancer |
| 03/11/2010 | US20100063091 Renin inhibitors |
| 03/11/2010 | US20100063087 5-Amino-4-Hydroxy-7-(Imidazo [1,2-A] Pyridin-6-Ylmethyl)-8-Methyl-Nonamide Derivatives and Related Compounds as Renin Inhibitors for the Treatment of Hypertension |
| 03/11/2010 | US20100063079 Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators |
| 03/11/2010 | US20100063076 Endothelin receptor antagonists |
| 03/11/2010 | US20100063071 Therapeutic compositions and related methods of use |
| 03/11/2010 | US20100063070 Combination for use in the treatment of inflammatory disorders |
| 03/11/2010 | US20100063067 Cyclic derivatives as modulators of chemokine receptor activity |
| 03/11/2010 | US20100063043 Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics |
| 03/11/2010 | US20100063035 Carbonic anhydrase inhibitors derivatives |
| 03/11/2010 | US20100063030 Benzenesulfonyl Compounds and the Use Thereof |
| 03/11/2010 | US20100063028 Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors |
| 03/11/2010 | US20100063025 Substituted isoquinoline and isoquinolinone derivatives as inhibitors of RHO-Kinase |
| 03/11/2010 | US20100063022 Novel compounds as cannabinoid receptor ligands |
| 03/11/2010 | US20100063018 orphan nuclear receptor modulators such as 23-N-Carbacinnamyloxy-3 alpha ,7 alpha -dihydroxy-5 beta -norcholanylamine, used for the treatment of liver, gastrointestinal, kidney, cardiovascular or metabolic disorders |
| 03/11/2010 | US20100063010 Method for administering a spill resistant pharmaceutical system |
| 03/11/2010 | US20100062992 Salts of 5-Azacytidine |
| 03/11/2010 | US20100062980 Therapeutic uses of beta-antagonists |
| 03/11/2010 | US20100062468 Methods and products related to low molecular weight heparin |
| 03/11/2010 | US20100062070 Pulverzed crystals of olmesartan medoxomil |
| 03/11/2010 | US20100062055 Lipid-based nitric oxide donors |
| 03/11/2010 | US20100062024 Biologically Active Hemagglutinin From Type A Clostridium Botulinum and Methods of Use |
| 03/11/2010 | US20100061966 Cardiac Stem Cells |
| 03/11/2010 | CA2736117A1 Compounds, compositions and methods of using same for modulating uric acid levels |
| 03/11/2010 | CA2735842A1 Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
| 03/11/2010 | CA2735826A1 Reducing cholesterol levels with combined use of quercetin and statin |
| 03/11/2010 | CA2735806A1 Aminotriazolopyridines and their use as kinase inhibitors |
| 03/11/2010 | CA2735653A1 Method of treating atrial fibrillation |
| 03/11/2010 | CA2735521A1 Indolizine inhibitors of leukotriene production |
| 03/10/2010 | EP2161282A1 Peptide analogues of PACAP |
| 03/10/2010 | EP2161280A2 Genes involved in the regulation of angiogenesis, pharmaceutical preparations containing them and their applications |
| 03/10/2010 | EP2161029A1 Composition comprising peptides |
| 03/10/2010 | EP2161028A1 Composition comprising peptides |
| 03/10/2010 | EP2160470A2 Chimeric pufa polyketide synthase systems and uses thereof |
| 03/10/2010 | EP2160404A1 Azapeptides as cd36 binding compounds |
| 03/10/2010 | EP2160196A2 Compounds for the treatment of ischemia and neurodegeneration |
| 03/10/2010 | EP2160190A1 5beta, 14beta-androstane derivatives useful for the treatment of restenosis after angioplastic or endoartherectomy and diseases due to organ fibrosis |
| 03/10/2010 | EP1973425B1 Novel use of a polyamine-depleted food composition for human or veterinary use, for preparing a therapeutic food product |
| 03/10/2010 | EP1605964B1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE |
| 03/10/2010 | EP1483588B1 Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders |
| 03/10/2010 | EP1423376B1 Bicyclic compound, production and use thereof |
| 03/10/2010 | EP1114061B1 FACTOR VIIa INHIBITORS |
| 03/10/2010 | CN101664388A transnasal transport/immunisation with highly adaptable carriers |
| 03/09/2010 | US7674830 Reducing blood glucose concentrations, weight loss, and treating diseases and conditions mediated by the cyclooxygenase-2 and 5-lipoxygenase enzymes; an enzyme inhibitors |
| 03/09/2010 | US7674825 Cardiovascular disorders; stimulant of guanylate cyclase |
| 03/09/2010 | US7674823 DNA-PK inhibitors |
| 03/09/2010 | US7674820 Ion channel modulating activity I |
| 03/09/2010 | US7674775 4-(N (S-glutathionylacetyl)amino)phenylarsenoxide (GSAO) and derivatives; antiinflammatory and antitumor agents; blood and autoimmune disorders; viral infections; anticoagulants |
| 03/09/2010 | US7674773 Glycosylated derivative of hypolipemic agents; side effect reduction; therapy for insulin resistance; hyperlipidemia agent; impaired lipid metabolism; lowering cholesterol levels |
| 03/09/2010 | US7674604 Using computer modeling to identify positions where cysteinal insertion will lock protein comprising integrin domain sequences into preferential configuration; directed protein evolution |
| 03/09/2010 | US7674463 Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist |
| 03/09/2010 | US7674455 treating a mammal having amyotrophic lateral sclerosis by transducing a motor neuron of the mammal with an insulin-like growth factor I (IGF-1) gene or a glial cell line-derived neurotrophic factor (GDNF) gene; neurodegenerative disorders |
| 03/09/2010 | CA2421819C Isoquinolinone potassium channel inhibitors |
| 03/09/2010 | CA2399813C Indol-3-yl derivatives |
| 03/09/2010 | CA2336702C Sulfonylaminocarboxylic acid n-arylamides as guanylate cyclase activators |
| 03/09/2010 | CA2311606C Use of purified sdg as a hypotensive (vasodilator) agent |
| 03/09/2010 | CA2306313C Dipeptide nitriles |
| 03/05/2010 | CA2639336A1 Therapeutic combinations and methods for cardiovascular improvement and treating cardiovascular disease |
| 03/04/2010 | WO2010025459A2 Novel anti-arrhythmia agent |
| 03/04/2010 | WO2010025370A2 Preparation of ranolazine |
| 03/04/2010 | WO2010025179A1 1-(4-ureidobenzoyl)piperazine derivatives |
| 03/04/2010 | WO2010025050A2 Affecting bone related conditions using cd68 blocking agents |
| 03/04/2010 | WO2010025043A1 Use of soluble epoxide hydrolase inhibitors in the treatment of inflammatory vascular diseases |
| 03/04/2010 | WO2010024772A1 Aspartyl protease inhibitors |
| 03/04/2010 | WO2010024393A1 Novel epigallocatechin gallate tetramer, and vascular endothelial function improver comprising same |
| 03/04/2010 | WO2010024298A1 Potassium channel regulator |
| 03/04/2010 | WO2010024258A1 Ring-fused azole derivative having pi3k-inhibiting activity |
| 03/04/2010 | WO2010024110A1 Oxotetrahydrofuran-2-yl-benzimidazole derivative |
| 03/04/2010 | WO2010023931A1 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same |
| 03/04/2010 | WO2010023858A1 Therapeutic agent for heart failure |
| 03/04/2010 | WO2010023181A1 Thienopyrimidines for pharmaceutical compositions |
| 03/04/2010 | WO2010009068A3 Cyclohexenyl modulators of chemokine receptor activity |
| 03/04/2010 | WO2010005581A4 Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad) |
| 03/04/2010 | WO2009149344A3 Solid states of aliskiren free base |
| 03/04/2010 | WO2009148620A3 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
| 03/04/2010 | WO2009106471A3 Angiotensin ii receptor blocker derivatives |
| 03/04/2010 | US20100056613 Spiroquinone compound and pharmaceutical composition |
| 03/04/2010 | US20100056610 HEPTbeta AS A TARGET IN TREATMENT OF ANGIOGENISIS MEDIATED DISORDERS |
| 03/04/2010 | US20100056603 Ion channel modulating compounds and uses thereof |
| 03/04/2010 | US20100056602 Substituted Pyrrole Derivatives And Their Use As HMG-CO Inhibitors |